Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Liver Transplantation | Research

Domino hepatocyte transplantation using explanted human livers with metabolic defects attenuates D-GalN/LPS-induced acute liver failure

Authors: Guang-Peng Zhou, Shi-Peng Li, Yi-Zhou Jiang, Jie Sun, Yu-Le Tan, Zhi-Gui Zeng, Lin Wei, Wei Qu, Li-Ying Sun, Zhi-Jun Zhu

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Explanted livers from patients with inherited metabolic liver diseases possess the potential to be a cell source of good-quality hepatocytes for hepatocyte transplantation (HT). This study evaluated the therapeutic effects of domino HT using hepatocytes isolated from explanted human livers for acute liver failure (ALF).

Methods

Isolated hepatocytes were evaluated for viability and function and then transplanted into d-galactosamine/lipopolysaccharide-induced ALF mice via splenic injection. The survival rate was analyzed by the Kaplan–Meier method and log-rank test. Liver function was evaluated by serum biochemical parameters, and inflammatory cytokine levels were measured by ELISA. The pathological changes in the liver tissues were assessed by hematoxylin–eosin staining. Hepatocyte apoptosis was investigated by TUNEL, and hepatocyte apoptosis-related proteins were detected by western blot. The localization of human hepatocytes in the injured mouse livers was detected by immunohistochemical analyses.

Results

Hepatocytes were successfully isolated from explanted livers of 10 pediatric patients with various liver-based metabolic disorders, with an average viability of 85.3% ± 13.0% and average yield of 9.2 × 106 ± 3.4 × 106 cells/g. Isolated hepatocytes had an excellent ability to secret albumin, produce urea, uptake indocyanine green, storage glycogen, and express alpha 1 antitrypsin, albumin, cytokeratin 18, and CYP3A4. Domino HT significantly reduced mortality, decreased serum levels of alanine aminotransferase and aspartate aminotransferase, and improved the pathological damage. Moreover, transplanted hepatocytes inhibited interleukin-6 and tumor necrosis factor-α levels. Domino HT also ameliorates hepatocyte apoptosis, as evidenced by decreased TUNEL positive cells. Positive staining for human albumin suggested the localization of human hepatocytes in ALF mice livers.

Conclusion

Explanted livers from patients with inheritable metabolic disorders can serve as a viable cell source for cell-based therapies. Domino HT using hepatocytes with certain metabolic defects has the potential to be a novel therapeutic strategy for ALF.
Literature
1.
go back to reference Ogura Y, Kabacam G, Singhal A, Moon DB. The role of living donor liver transplantation for acute liver failure. Int J Surg. 2020;82:145–8.CrossRef Ogura Y, Kabacam G, Singhal A, Moon DB. The role of living donor liver transplantation for acute liver failure. Int J Surg. 2020;82:145–8.CrossRef
2.
3.
go back to reference Reddy KR, Ellerbe C, Schilsky M, Stravitz RT, Fontana RJ, Durkalski V, Lee WM, Acute Liver Failure Study G. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. Liver Transpl. 2016;22:505–15.CrossRef Reddy KR, Ellerbe C, Schilsky M, Stravitz RT, Fontana RJ, Durkalski V, Lee WM, Acute Liver Failure Study G. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. Liver Transpl. 2016;22:505–15.CrossRef
4.
go back to reference Dhawan A, Chaijitraruch N, Fitzpatrick E, Bansal S, Filippi C, Lehec SC, Heaton ND, Kane P, Verma A, Hughes RD, et al. Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children. J Hepatol. 2020;72:877–84.CrossRef Dhawan A, Chaijitraruch N, Fitzpatrick E, Bansal S, Filippi C, Lehec SC, Heaton ND, Kane P, Verma A, Hughes RD, et al. Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children. J Hepatol. 2020;72:877–84.CrossRef
5.
go back to reference Zhou GP, Jiang YZ, Sun LY, Zhu ZJ. Therapeutic effect and safety of stem cell therapy for chronic liver disease: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Therapy. 2020;11:419.CrossRef Zhou GP, Jiang YZ, Sun LY, Zhu ZJ. Therapeutic effect and safety of stem cell therapy for chronic liver disease: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Therapy. 2020;11:419.CrossRef
6.
go back to reference Iansante V, Chandrashekran A, Dhawan A. Cell-based liver therapies: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2018;373:20170229.CrossRef Iansante V, Chandrashekran A, Dhawan A. Cell-based liver therapies: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2018;373:20170229.CrossRef
7.
go back to reference Iansante V, Mitry RR, Filippi C, Fitzpatrick E, Dhawan A. Human hepatocyte transplantation for liver disease: current status and future perspectives. Pediatr Res. 2018;83:232–40.CrossRef Iansante V, Mitry RR, Filippi C, Fitzpatrick E, Dhawan A. Human hepatocyte transplantation for liver disease: current status and future perspectives. Pediatr Res. 2018;83:232–40.CrossRef
8.
go back to reference Miki T. Clinical hepatocyte transplantation. Gastroenterol Hepatol. 2019;42:202–8.CrossRef Miki T. Clinical hepatocyte transplantation. Gastroenterol Hepatol. 2019;42:202–8.CrossRef
9.
go back to reference Enosawa S, Horikawa R, Yamamoto A, Sakamoto S, Shigeta T, Nosaka S, Fujimoto J, Nakazawa A, Tanoue A, Nakamura K, et al. Hepatocyte transplantation using a living donor reduced graft in a baby with ornithine transcarbamylase deficiency: a novel source of hepatocytes. Liver Transpl. 2014;20:391–3.CrossRef Enosawa S, Horikawa R, Yamamoto A, Sakamoto S, Shigeta T, Nosaka S, Fujimoto J, Nakazawa A, Tanoue A, Nakamura K, et al. Hepatocyte transplantation using a living donor reduced graft in a baby with ornithine transcarbamylase deficiency: a novel source of hepatocytes. Liver Transpl. 2014;20:391–3.CrossRef
10.
go back to reference Stephenne X, Debray FG, Smets F, Jazouli N, Sana G, Tondreau T, Menten R, Goffette P, Boemer F, Schoos R, et al. Hepatocyte transplantation using the domino concept in a child with tetrabiopterin nonresponsive phenylketonuria. Cell Transplant. 2012;21:2765–70.CrossRef Stephenne X, Debray FG, Smets F, Jazouli N, Sana G, Tondreau T, Menten R, Goffette P, Boemer F, Schoos R, et al. Hepatocyte transplantation using the domino concept in a child with tetrabiopterin nonresponsive phenylketonuria. Cell Transplant. 2012;21:2765–70.CrossRef
11.
go back to reference Gramignoli R, Tahan V, Dorko K, Skvorak KJ, Hansel MC, Zhao W, Venkataramanan R, Ellis EC, Jorns C, Ericzon BG, et al. New potential cell source for hepatocyte transplantation: discarded livers from metabolic disease liver transplants. Stem Cell Res. 2013;11:563–73.CrossRef Gramignoli R, Tahan V, Dorko K, Skvorak KJ, Hansel MC, Zhao W, Venkataramanan R, Ellis EC, Jorns C, Ericzon BG, et al. New potential cell source for hepatocyte transplantation: discarded livers from metabolic disease liver transplants. Stem Cell Res. 2013;11:563–73.CrossRef
12.
go back to reference Zhou GP, Sun LY, Zhu ZJ. The concept of “domino” in liver and hepatocyte transplantation. Thera Adv Gastroenterol. 2020;13:1756284820968755.CrossRef Zhou GP, Sun LY, Zhu ZJ. The concept of “domino” in liver and hepatocyte transplantation. Thera Adv Gastroenterol. 2020;13:1756284820968755.CrossRef
13.
go back to reference Bartlett DC, Newsome PN. A modified protocol for the isolation of primary human hepatocytes with improved viability and function from normal and diseased human liver. Methods Mol Biol. 2017;1506:61–73.CrossRef Bartlett DC, Newsome PN. A modified protocol for the isolation of primary human hepatocytes with improved viability and function from normal and diseased human liver. Methods Mol Biol. 2017;1506:61–73.CrossRef
14.
go back to reference Das B, Bhattacharjee J, Preeti Mishra A, Jain K, Iyer S, Kesarwani A, Sahu P, Sinha P, Nagarajan P, et al. Intrasplenic transplantation of hepatocytes after partial hepatectomy in NOD.SCID mice. J Vis Exp. 2018;132:56018. Das B, Bhattacharjee J, Preeti Mishra A, Jain K, Iyer S, Kesarwani A, Sahu P, Sinha P, Nagarajan P, et al. Intrasplenic transplantation of hepatocytes after partial hepatectomy in NOD.SCID mice. J Vis Exp. 2018;132:56018.
15.
go back to reference Wang F, Zhou L, Ma X, Ma W, Wang C, Lu Y, Chen Y, An L, An W, Yang Y. Monitoring of intrasplenic hepatocyte transplantation for acute-on-chronic liver failure: a prospective five-year follow-up study. Transplant Proc. 2014;46:192–8.CrossRef Wang F, Zhou L, Ma X, Ma W, Wang C, Lu Y, Chen Y, An L, An W, Yang Y. Monitoring of intrasplenic hepatocyte transplantation for acute-on-chronic liver failure: a prospective five-year follow-up study. Transplant Proc. 2014;46:192–8.CrossRef
16.
go back to reference Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation. 2006;82:441–9.CrossRef Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation. 2006;82:441–9.CrossRef
17.
go back to reference Zeng ZG, Zhou GP, Wei L, Qu W, Liu Y, Tan YL, Wang J, Sun LY, Zhu ZJ. Therapeutic potential of living donor liver transplantation from heterozygous carrier donors in children with propionic acidemia. Orphanet J Rare Dis. 2022;17:62.CrossRef Zeng ZG, Zhou GP, Wei L, Qu W, Liu Y, Tan YL, Wang J, Sun LY, Zhu ZJ. Therapeutic potential of living donor liver transplantation from heterozygous carrier donors in children with propionic acidemia. Orphanet J Rare Dis. 2022;17:62.CrossRef
18.
go back to reference Zhou GP, Jiang YZ, Wu SS, Kong YY, Sun LY, Zhu ZJ. Liver transplantation for propionic acidemia: evidence from a systematic review and meta-analysis. Transplantation. 2021;105:2272–82.CrossRef Zhou GP, Jiang YZ, Wu SS, Kong YY, Sun LY, Zhu ZJ. Liver transplantation for propionic acidemia: evidence from a systematic review and meta-analysis. Transplantation. 2021;105:2272–82.CrossRef
19.
go back to reference Jiang YZ, Zhou GP, Wu SS, Kong YY, Zhu ZJ, Sun LY. Safety and efficacy of liver transplantation for methylmalonic acidemia: a systematic review and meta-analysis. Transplant Rev (Orlando). 2021;35:100592.CrossRef Jiang YZ, Zhou GP, Wu SS, Kong YY, Zhu ZJ, Sun LY. Safety and efficacy of liver transplantation for methylmalonic acidemia: a systematic review and meta-analysis. Transplant Rev (Orlando). 2021;35:100592.CrossRef
20.
go back to reference McKiernan PJ, Ganoza A, Squires JE, Squires RH, Vockley J, Mazariegos G, Soltys K, Sun Q, Sindhi R. Evolving trends in liver transplant for metabolic liver disease in the United States. Liver Transpl. 2019;25:911–21.CrossRef McKiernan PJ, Ganoza A, Squires JE, Squires RH, Vockley J, Mazariegos G, Soltys K, Sun Q, Sindhi R. Evolving trends in liver transplant for metabolic liver disease in the United States. Liver Transpl. 2019;25:911–21.CrossRef
21.
go back to reference Jiang YZ, Sun LY, Zhu ZJ, Wei L, Qu W, Zeng ZG, Liu Y, Tan YL, He EH, Xu RF, et al. Perioperative characteristics and management of liver transplantation for isolated methylmalonic acidemia-the largest experience in China. Hepatobiliary Surg Nutr. 2019;8:470–9.CrossRef Jiang YZ, Sun LY, Zhu ZJ, Wei L, Qu W, Zeng ZG, Liu Y, Tan YL, He EH, Xu RF, et al. Perioperative characteristics and management of liver transplantation for isolated methylmalonic acidemia-the largest experience in China. Hepatobiliary Surg Nutr. 2019;8:470–9.CrossRef
22.
go back to reference Bierwolf J, Lutgehetmann M, Deichmann S, Erbes J, Volz T, Dandri M, Cohen S, Nashan B, Pollok JM. Primary human hepatocytes from metabolic-disordered children recreate highly differentiated liver-tissue-like spheroids on alginate scaffolds. Tissue Eng Part A. 2012;18:1443–53.CrossRef Bierwolf J, Lutgehetmann M, Deichmann S, Erbes J, Volz T, Dandri M, Cohen S, Nashan B, Pollok JM. Primary human hepatocytes from metabolic-disordered children recreate highly differentiated liver-tissue-like spheroids on alginate scaffolds. Tissue Eng Part A. 2012;18:1443–53.CrossRef
23.
go back to reference Marques HP, Barros I, Li J, Murad SD, di Benedetto F. Current update in domino liver transplantation. Int J Surg. 2020;82s:163–8.CrossRef Marques HP, Barros I, Li J, Murad SD, di Benedetto F. Current update in domino liver transplantation. Int J Surg. 2020;82s:163–8.CrossRef
24.
go back to reference Qu W, Wei L, Zhu ZJ, Sun LY, Liu Y, Zeng ZG. Considerations for use of domino cross-auxiliary liver transplantation in metabolic liver diseases: a review of case studies. Transplantation. 2019;103:1916–20.CrossRef Qu W, Wei L, Zhu ZJ, Sun LY, Liu Y, Zeng ZG. Considerations for use of domino cross-auxiliary liver transplantation in metabolic liver diseases: a review of case studies. Transplantation. 2019;103:1916–20.CrossRef
25.
go back to reference Zhu ZJ, Wei L, Qu W, Sun LY, Liu Y, Zeng ZG, Zhang L, He EH, Zhang HM, Jia JD, et al. First case of cross-auxiliary double domino donor liver transplantation. World J Gastroenterol. 2017;23:7939–44.CrossRef Zhu ZJ, Wei L, Qu W, Sun LY, Liu Y, Zeng ZG, Zhang L, He EH, Zhang HM, Jia JD, et al. First case of cross-auxiliary double domino donor liver transplantation. World J Gastroenterol. 2017;23:7939–44.CrossRef
26.
go back to reference Cardoso L, Moreira LFP, Pinto MA, Henriques-Pons A, Alves LA. Domino hepatocyte transplantation: a therapeutic alternative for the treatment of acute liver failure. Can J Gastroenterol Hepatol. 2018;2018:2593745.CrossRef Cardoso L, Moreira LFP, Pinto MA, Henriques-Pons A, Alves LA. Domino hepatocyte transplantation: a therapeutic alternative for the treatment of acute liver failure. Can J Gastroenterol Hepatol. 2018;2018:2593745.CrossRef
27.
go back to reference Lee CA, Dhawan A, Iansante V, Lehec S, Khorsandi SE, Filippi C, Walker S, Fernandez-Dacosta R, Heaton N, Bansal S, et al. Cryopreserved neonatal hepatocytes may be a source for transplantation: Evaluation of functionality toward clinical use. Liver Transpl. 2018;24:394–406.CrossRef Lee CA, Dhawan A, Iansante V, Lehec S, Khorsandi SE, Filippi C, Walker S, Fernandez-Dacosta R, Heaton N, Bansal S, et al. Cryopreserved neonatal hepatocytes may be a source for transplantation: Evaluation of functionality toward clinical use. Liver Transpl. 2018;24:394–406.CrossRef
28.
go back to reference Mc Kiernan PJ. Recent advances in liver transplantation for metabolic disease. J Inherit Metab Dis. 2017;40:491–5.CrossRef Mc Kiernan PJ. Recent advances in liver transplantation for metabolic disease. J Inherit Metab Dis. 2017;40:491–5.CrossRef
29.
go back to reference Mazariegos G, Shneider B, Burton B, Fox IJ, Hadzic N, Kishnani P, Morton DH, McIntire S, Sokol RJ, Summar M, et al. Liver transplantation for pediatric metabolic disease. Mol Genet Metab. 2014;111:418–27.CrossRef Mazariegos G, Shneider B, Burton B, Fox IJ, Hadzic N, Kishnani P, Morton DH, McIntire S, Sokol RJ, Summar M, et al. Liver transplantation for pediatric metabolic disease. Mol Genet Metab. 2014;111:418–27.CrossRef
30.
go back to reference Barahman M, Zhang W, Harris HY, Aiyer A, Kabarriti R, Kinkhabwala M, Roy-Chowdhury N, Beck AP, Scanlan TS, Roy-Chowdhury J, et al. Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis. J Hepatol. 2019;70:1170–9.CrossRef Barahman M, Zhang W, Harris HY, Aiyer A, Kabarriti R, Kinkhabwala M, Roy-Chowdhury N, Beck AP, Scanlan TS, Roy-Chowdhury J, et al. Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis. J Hepatol. 2019;70:1170–9.CrossRef
31.
go back to reference Fontes P, Komori J, Lopez R, Marsh W, Lagasse E. Development of ectopic livers by hepatocyte transplantation into swine lymph nodes. Liver Transpl. 2020;26:1629–43.CrossRef Fontes P, Komori J, Lopez R, Marsh W, Lagasse E. Development of ectopic livers by hepatocyte transplantation into swine lymph nodes. Liver Transpl. 2020;26:1629–43.CrossRef
32.
go back to reference Wang L, Wang C, Wang Z, Gan J, Liu C, Xia S, Niu Y, Chen D, Zhang J, Dong L. Transforming the spleen into a liver-like organ in vivo. Sci Adv. 2020;6:eaaz9974.CrossRef Wang L, Wang C, Wang Z, Gan J, Liu C, Xia S, Niu Y, Chen D, Zhang J, Dong L. Transforming the spleen into a liver-like organ in vivo. Sci Adv. 2020;6:eaaz9974.CrossRef
33.
go back to reference Mu W, Wang Q, Jia M, Dong S, Li S, Yang J, Liu G. Hepatoprotective effects of albumin-encapsulated nanoparticles of a curcumin derivative COP-22 against lipopolysaccharide/D-galactosamine-induced acute liver injury in mice. Int J Mol Sci. 2022;23:4903.CrossRef Mu W, Wang Q, Jia M, Dong S, Li S, Yang J, Liu G. Hepatoprotective effects of albumin-encapsulated nanoparticles of a curcumin derivative COP-22 against lipopolysaccharide/D-galactosamine-induced acute liver injury in mice. Int J Mol Sci. 2022;23:4903.CrossRef
Metadata
Title
Domino hepatocyte transplantation using explanted human livers with metabolic defects attenuates D-GalN/LPS-induced acute liver failure
Authors
Guang-Peng Zhou
Shi-Peng Li
Yi-Zhou Jiang
Jie Sun
Yu-Le Tan
Zhi-Gui Zeng
Lin Wei
Wei Qu
Li-Ying Sun
Zhi-Jun Zhu
Publication date
01-12-2022

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.